Joseph Paul Eder, MD

Professor of Medicine (Medical Oncology)

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale

Medical Oncology: Early Drug Development Program

Yale Medical Group

Clinical Trials

Conditions Study Title
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, Soft Tissue, Stomach A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, Stomach A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Bladder, Breast - Female, Lung, Pancreas, Stomach A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Bladder, Brain and Nervous System, Breast - Female, Colon, Esophagus, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Endocrine System, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Cancer with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents PRO-02
Breast - Female, Lung, Ovary AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0575 ADMINISTERED ALONE AND IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH REFRACTORY SOLID TUMORS OR LYMPHOMA
Bladder, Colon, Lip, Oral Cavity and Pharynx, Lung A Phase 1 Study of MEDI6383 (an OX40 Agonist) in Adult Subjects with Select Advanced Solid Tumors
Bladder, Breast - Female, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Pancreas, Soft Tissue, Stomach A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously Part A: A Dose-Escalation Study in Patients with Advanced Solid Tumors Part B: An Expansion Cohort in Patients with Selected Malignancies
Colon, Lung A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A AND COBIMETINIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCERS WITH MUTANT KRAS
Bladder, Breast - Female, Colon, Lung, Pancreas A Phase 1b/2, multi-center, uncontrolled, open-label, dose escalation study of refametinib (BAY 86-9766) in combination with regorafenib (BAY 73-4506) in patients with advanced or metastatic cancer
Kidney, Melanoma, skin A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects with Advanced Malignancies
Breast - Female, Lung, Pancreas A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS
Breast - Female An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of oral BAY 1161909 in combination with weekly intravenous paclitaxel given in an intermittent dosing schedule in subjects with advanced malignancies
Other Digestive Organ, Unknown Sites Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Bladder, Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, Other Female Genital, Other Skin, Ovary, Pancreas A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

Edit this profile

Contact Info

Joseph Paul Eder, MD
Patient Care Location
Smilow Cancer Hospital at Yale - New Haven
35 Park Street

New Haven, CT 06511
Office Location
Winchester Building
25 York Street, Ste 211

New Haven, CT 06511
Mailing Address
Yale Cancer CenterPO Box 208028
New Haven, CT 06520-8028

Curriculum Vitae